Institute of Hematology, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, Tel-Aviv University, Israel.
Acta Haematol. 2011;125(1-2):68-79. doi: 10.1159/000318898. Epub 2010 Dec 8.
Myeloid colony-stimulating factors (M-CSFs), which include granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF), regulate the proliferation and differentiation of myeloid cells. Their use has an important role in the treatment of hematologic malignancies. Guidelines for the use of colony stimulating factors have been published by the American Society of Oncology (ASCO) in 1996 and have been updated several times, most recently in 2006. Meta-analyses of randomized controlled trials are regarded as the highest grade of evidence in clinical research and as such, compared to individual studies, they have more power in answering unresolved clinical issues. In this review, our aim is to evaluate the role of M-CSFs in hematologic malignancies based on meta-analyses conducted in the field.
髓系集落刺激因子(M-CSFs)包括粒细胞集落刺激因子(G-CSF)和粒细胞-巨噬细胞集落刺激因子(GM-CSF),调节髓系细胞的增殖和分化。它们在治疗血液系统恶性肿瘤方面具有重要作用。美国临床肿瘤学会(ASCO)于 1996 年发布了集落刺激因子使用指南,并已多次更新,最近一次是在 2006 年。随机对照试验的荟萃分析被认为是临床研究中最高级别的证据,因此与单独的研究相比,它们在回答未解决的临床问题方面更有说服力。在这篇综述中,我们的目的是根据该领域的荟萃分析来评估 M-CSFs 在血液系统恶性肿瘤中的作用。